Endpoints News 24 févr. 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News 23 févr. 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Endpoints News 9 févr. 2026 Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Endpoints News 4 févr. 2026 Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
FierceBiotech 28 janv. 2026 With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera
FierceBiotech 21 janv. 2026 Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
Endpoints News 16 janv. 2026 Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai
Endpoints News 15 janv. 2026 A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit
Endpoints News 15 janv. 2026 FDA to meet Novo Nordisk on troubled site; AbbVie buys drug-device factory
FierceBiotech 15 janv. 2026 Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
Endpoints News 15 janv. 2026 Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035
Endpoints News 12 janv. 2026 #JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom
Endpoints News 5 janv. 2026 Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash